Podcast appearances and mentions of Suresh S Ramalingam

  • 24PODCASTS
  • 63EPISODES
  • 1hAVG DURATION
  • 1WEEKLY EPISODE
  • Nov 25, 2024LATEST

POPULARITY

20172018201920202021202220232024


Best podcasts about Suresh S Ramalingam

Latest podcast episodes about Suresh S Ramalingam

Research To Practice | Oncology Videos
Lung Cancer | The Implications of Recent Datasets for the Current and Future Management of Lung Cancer — A Review of Information from ESMO Congress 2024 and Other Conferences

Research To Practice | Oncology Videos

Play Episode Listen Later Nov 25, 2024 60:12


Featuring perspectives from Dr Suresh S Ramalingam and Dr Gregory J Riely, including the following topics: Introduction: Tumor Treating Fields (0:00) Nontargeted Therapy for Lung Cancer — Dr Ramalingam (4:02) Targeted Therapy for Non-Small Cell Lung Cancer — Dr Riely (33:50) CME information and select publications

Lung Cancer Update
The Implications of Recent Datasets for the Current and Future Management of Lung Cancer — A Review of Information from ESMO Congress 2024 and Other Conferences

Lung Cancer Update

Play Episode Listen Later Nov 25, 2024 60:11


Dr Suresh S Ramalingam from the Emory University School of Medicine in Atlanta, Georgia and Dr Gregory J Riely from Memorial Sloan Kettering Cancer Center in New York, New York discuss the implications of recent data sets for the current and future management of lung cancer.

Oncology Today with Dr Neil Love
The Implications of Recent Datasets for the Current and Future Management of Lung Cancer — A Review of Information from ESMO Congress 2024 and Other Conferences

Oncology Today with Dr Neil Love

Play Episode Listen Later Nov 22, 2024 60:11


Dr Suresh S Ramalingam from the Emory University School of Medicine in Atlanta, Georgia, and Dr Gregory J Riely from Memorial Sloan Kettering Cancer Center in New York, New York, discuss the implications of recent data sets for the current and future management of lung cancer, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/PostESMO24/Lung).

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
Suresh S. Ramalingam, MD, FACP, FASCO - Elevating Expectations, Broadening Impact: How to Leverage Immunotherapy and EGFR-Targeted Therapy to Improve Outcomes in Unresectable Stage III NSCLC

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast

Play Episode Listen Later Oct 4, 2024 55:58


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete EBAC/CME information, and to apply for credit, please visit us at PeerView.com/BVU865. EBAC/CME credit will be available until October 7, 2025.Elevating Expectations, Broadening Impact: How to Leverage Immunotherapy and EGFR-Targeted Therapy to Improve Outcomes in Unresectable Stage III NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Suresh S. Ramalingam, MD, FACP, FASCO - Elevating Expectations, Broadening Impact: How to Leverage Immunotherapy and EGFR-Targeted Therapy to Improve Outcomes in Unresectable Stage III NSCLC

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Oct 4, 2024 55:59


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete EBAC/CME information, and to apply for credit, please visit us at PeerView.com/BVU865. EBAC/CME credit will be available until October 7, 2025.Elevating Expectations, Broadening Impact: How to Leverage Immunotherapy and EGFR-Targeted Therapy to Improve Outcomes in Unresectable Stage III NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Suresh S. Ramalingam, MD, FACP, FASCO - Elevating Expectations, Broadening Impact: How to Leverage Immunotherapy and EGFR-Targeted Therapy to Improve Outcomes in Unresectable Stage III NSCLC

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Oct 4, 2024 55:58


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete EBAC/CME information, and to apply for credit, please visit us at PeerView.com/BVU865. EBAC/CME credit will be available until October 7, 2025.Elevating Expectations, Broadening Impact: How to Leverage Immunotherapy and EGFR-Targeted Therapy to Improve Outcomes in Unresectable Stage III NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Suresh S. Ramalingam, MD, FACP, FASCO - Elevating Expectations, Broadening Impact: How to Leverage Immunotherapy and EGFR-Targeted Therapy to Improve Outcomes in Unresectable Stage III NSCLC

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Oct 4, 2024 55:58


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete EBAC/CME information, and to apply for credit, please visit us at PeerView.com/BVU865. EBAC/CME credit will be available until October 7, 2025.Elevating Expectations, Broadening Impact: How to Leverage Immunotherapy and EGFR-Targeted Therapy to Improve Outcomes in Unresectable Stage III NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Suresh S. Ramalingam, MD, FACP, FASCO - Elevating Expectations, Broadening Impact: How to Leverage Immunotherapy and EGFR-Targeted Therapy to Improve Outcomes in Unresectable Stage III NSCLC

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Oct 4, 2024 55:59


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete EBAC/CME information, and to apply for credit, please visit us at PeerView.com/BVU865. EBAC/CME credit will be available until October 7, 2025.Elevating Expectations, Broadening Impact: How to Leverage Immunotherapy and EGFR-Targeted Therapy to Improve Outcomes in Unresectable Stage III NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Suresh S. Ramalingam, MD, FACP, FASCO - Elevating Expectations, Broadening Impact: How to Leverage Immunotherapy and EGFR-Targeted Therapy to Improve Outcomes in Unresectable Stage III NSCLC

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Oct 4, 2024 55:59


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete EBAC/CME information, and to apply for credit, please visit us at PeerView.com/BVU865. EBAC/CME credit will be available until October 7, 2025.Elevating Expectations, Broadening Impact: How to Leverage Immunotherapy and EGFR-Targeted Therapy to Improve Outcomes in Unresectable Stage III NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
Suresh S. Ramalingam, MD, FACP, FASCO - Elevating Expectations, Broadening Impact: How to Leverage Immunotherapy and EGFR-Targeted Therapy to Improve Outcomes in Unresectable Stage III NSCLC

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast

Play Episode Listen Later Oct 4, 2024 55:59


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete EBAC/CME information, and to apply for credit, please visit us at PeerView.com/BVU865. EBAC/CME credit will be available until October 7, 2025.Elevating Expectations, Broadening Impact: How to Leverage Immunotherapy and EGFR-Targeted Therapy to Improve Outcomes in Unresectable Stage III NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

PeerView Clinical Pharmacology CME/CNE/CPE Video
Suresh S. Ramalingam, MD, FACP, FASCO - Elevating Expectations, Broadening Impact: How to Leverage Immunotherapy and EGFR-Targeted Therapy to Improve Outcomes in Unresectable Stage III NSCLC

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Oct 4, 2024 55:58


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete EBAC/CME information, and to apply for credit, please visit us at PeerView.com/BVU865. EBAC/CME credit will be available until October 7, 2025.Elevating Expectations, Broadening Impact: How to Leverage Immunotherapy and EGFR-Targeted Therapy to Improve Outcomes in Unresectable Stage III NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

OBR Peer-Spectives
What "Incredibly Dramatic" Data on Osimertinib in NSCLC Mean for Practice

OBR Peer-Spectives

Play Episode Listen Later Aug 28, 2024 9:47


Results of the phase 3 LAURA clinical trial, presented at the 2024 American Society of Clinical Oncology Annual Meeting, showed that osimertinib significantly improves progression-free survival in patients with unresectable stage III EGFR-mutant non-small cell lung cancer (NSCLC) after chemoradiotherapy. “The benefits of osimertinib in this patient population when compared to placebo are just incredibly dramatic,” noted Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at the Cedars-Sinai Cancer Center in Los Angeles. He spoke with lead study author Suresh S. Ramalingam, MD, the Roberto C. Goizueta Distinguished Chair for Cancer Research and the executive director at the Winship Cancer Institute of Emory University in Atlanta, about how oncologists should adjust their practice in the wake of these key findings. Dr. Ramalingam tackled questions about the optimal duration of osimertinib therapy, toxicity concerns, and notable benefits seen in the LAURA data. “Osimertinib reduced both intrathoracic progression and extrathoracic progression, particularly intracranial progression,” he noted. Dr. Ramalingam reported research funding from Amgen, AstraZeneca/MedImmune, Bristol Myers Squibb, Merck, Pfizer, and Takeda; travel, accommodations, and other expenses from AbbVie; and a relationship with the American Cancer Society. Dr. Figlin reported various financial relationships.

2036: The Podcast
2O36: A Future Where Cancer Patients Survive and Thrive

2036: The Podcast

Play Episode Listen Later Sep 6, 2022 15:22


When it comes to treating cancer, what was not possible just a few years ago is now possible. In this episode, Dr. Suresh S. Ramalingam, the executive director of Winship Cancer Institute of Emory University, speaks with Emory School of Medicine student Carey Jansen about the advances in research, patient care, and education that are leading to long-term survival and a better quality of life for people with cancer. Our GDPR privacy policy was updated on August 8, 2022. Visit acast.com/privacy for more information.

PrecisCa Oncology Podcast : Precision Cancer Insights
Suresh Ramalingam MD, FACP, FASCO | Lung Cancer Staging, Targeted Therapies, Side Effects & Clinical Trials

PrecisCa Oncology Podcast : Precision Cancer Insights

Play Episode Listen Later Apr 25, 2022 25:16


On this episode, PrecisCa speaks with Dr. Suresh Ramalingam, medical oncologist and Executive Director at the Winship Cancer Institute of Emory University in Atlanta, Georgia.   Dr. Ramalingam sits down with us to answer the following questions: What is the prognosis of lung cancer by stage? What are the side effects of targeted therapy for lung cancer & how do you manage them? Do you ever use immunotherapy in patients with driver mutations? What are the concerns about sequencing of immunotherapy and targeted agents? How do you treat metastatic EGFR mutated lung cancer in First, Second and Third line settings? How do you approach brain metastases in EGFR-mutated lung cancer? What are the modalities that can be used to treat brain metastases and how do the different TKI's compare in terms of brain metastases? What are the benefits of enrolling in a clinical trial? Board certified in medical oncology, Suresh S. Ramalingam, MD, FACP, FASCO, is nationally recognized as an investigator and a physician in the area of small cell and non-small cell lung cancer. Dr. Ramalingam serves as executive director of Winship Cancer Institute of Emory University and associate vice president for cancer of Woodruff Health Sciences Center. He is past-president of the Georgia Society of Oncology and a member of the board of Georgia CORE. He is a Fellow of the American Society of Clinical Oncology and a Georgia Cancer Coalition Distinguished Cancer Scholar. Dr. Ramalingam holds professional memberships with American Society of Clinical Oncology, American Association for Cancer Research, and International Association of Lung Cancer Study. He plays an active role in the ECOG-ACRIN Cancer Research Group as the Chair of the Thoracic Malignancies Committee and as the Deputy Chair of Therapeutics Programs. He serves on several international, national and institutional committees. He is a member of the Medical Oncology Board Exam Committee for American Board of Internal Medicine.  Visit www.precisca.com for more resources, content, and access to our entire catalogue of educational content. There you will have access to our complete library of educational videos. New episodes of the PrecisCa Oncology Podcast are released weekly. Please consider sharing our podcast, subscribing & turning on notifications to be the first to know about new releases. Together, we can raise the level of cancer care from diagnosis to recovery.  

PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
Suresh S. Ramalingam, MD, FACP, FASCO / Arjun Balar, MD / Yelena Janjigian, MD - Revisiting PD-L1 as an Immunotherapy Biomarker Across the Cancer Spectrum: Current and Emerging Standards of Testing, Scoring, and Assay Interpretation

PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jun 21, 2021 93:30


Go online to PeerView.com/CYY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies have transformed the treatment of many tumors. With the remarkable expansion of checkpoint inhibitors and combinations across the cancer spectrum, reliable predictive biomarkers are essential to guide clinical decisions about treatment selection. PD-L1 expression is the most established immunotherapy biomarker, and several others are in clinical use or showing promise. However, many research questions and practical challenges remain about biomarker testing, scoring, and interpretation in different tumors to identify patients who are most likely to benefit from cancer immunotherapies. This PeerView Clinical and Laboratory Accelerator based on a recent web broadcast provides practical guidance for navigating the complexities of cancer immunotherapy biomarker testing. Oncology and pathology experts focus on the nuances of PD-L1 expression assessment, along with other relevant biomarkers, in different solid tumors and how to use this information to direct clinical decisions regarding treatment selection for appropriate patients. Ongoing research efforts and innovations to refine and expand the role of cancer immunotherapy biomarkers are explored as well. Upon completion of this accredited CE activity, participants should be better able to: Assess the latest evidence on PD-L1 as a pan-tumor biomarker and the rationale for its use to predict benefit from cancer immunotherapies, Analyze practical considerations and complexities of PD-L1 biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, standardization/harmonization options, cut points, digital pathology, artificial intelligence/machine learning, and other nuances, Incorporate the latest evidence and recommendations for PD-L1 biomarker testing in clinical and laboratory settings across tumor types, Integrate appropriate strategies for interdisciplinary collaboration and coordination among all members of the healthcare team to optimize the selection and interpretation of PD-L1 biomarker testing to guide clinical decision-making.

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Suresh S. Ramalingam, MD, FACP, FASCO / Arjun Balar, MD / Yelena Janjigian, MD - Revisiting PD-L1 as an Immunotherapy Biomarker Across the Cancer Spectrum: Current and Emerging Standards of Testing, Scoring, and Assay Interpretation

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Jun 21, 2021 93:59


Go online to PeerView.com/CYY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies have transformed the treatment of many tumors. With the remarkable expansion of checkpoint inhibitors and combinations across the cancer spectrum, reliable predictive biomarkers are essential to guide clinical decisions about treatment selection. PD-L1 expression is the most established immunotherapy biomarker, and several others are in clinical use or showing promise. However, many research questions and practical challenges remain about biomarker testing, scoring, and interpretation in different tumors to identify patients who are most likely to benefit from cancer immunotherapies. This PeerView Clinical and Laboratory Accelerator based on a recent web broadcast provides practical guidance for navigating the complexities of cancer immunotherapy biomarker testing. Oncology and pathology experts focus on the nuances of PD-L1 expression assessment, along with other relevant biomarkers, in different solid tumors and how to use this information to direct clinical decisions regarding treatment selection for appropriate patients. Ongoing research efforts and innovations to refine and expand the role of cancer immunotherapy biomarkers are explored as well. Upon completion of this accredited CE activity, participants should be better able to: Assess the latest evidence on PD-L1 as a pan-tumor biomarker and the rationale for its use to predict benefit from cancer immunotherapies, Analyze practical considerations and complexities of PD-L1 biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, standardization/harmonization options, cut points, digital pathology, artificial intelligence/machine learning, and other nuances, Incorporate the latest evidence and recommendations for PD-L1 biomarker testing in clinical and laboratory settings across tumor types, Integrate appropriate strategies for interdisciplinary collaboration and coordination among all members of the healthcare team to optimize the selection and interpretation of PD-L1 biomarker testing to guide clinical decision-making.

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Suresh S. Ramalingam, MD, FACP, FASCO / Arjun Balar, MD / Yelena Janjigian, MD - Revisiting PD-L1 as an Immunotherapy Biomarker Across the Cancer Spectrum: Current and Emerging Standards of Testing, Scoring, and Assay Interpretation

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jun 21, 2021 93:30


Go online to PeerView.com/CYY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies have transformed the treatment of many tumors. With the remarkable expansion of checkpoint inhibitors and combinations across the cancer spectrum, reliable predictive biomarkers are essential to guide clinical decisions about treatment selection. PD-L1 expression is the most established immunotherapy biomarker, and several others are in clinical use or showing promise. However, many research questions and practical challenges remain about biomarker testing, scoring, and interpretation in different tumors to identify patients who are most likely to benefit from cancer immunotherapies. This PeerView Clinical and Laboratory Accelerator based on a recent web broadcast provides practical guidance for navigating the complexities of cancer immunotherapy biomarker testing. Oncology and pathology experts focus on the nuances of PD-L1 expression assessment, along with other relevant biomarkers, in different solid tumors and how to use this information to direct clinical decisions regarding treatment selection for appropriate patients. Ongoing research efforts and innovations to refine and expand the role of cancer immunotherapy biomarkers are explored as well. Upon completion of this accredited CE activity, participants should be better able to: Assess the latest evidence on PD-L1 as a pan-tumor biomarker and the rationale for its use to predict benefit from cancer immunotherapies, Analyze practical considerations and complexities of PD-L1 biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, standardization/harmonization options, cut points, digital pathology, artificial intelligence/machine learning, and other nuances, Incorporate the latest evidence and recommendations for PD-L1 biomarker testing in clinical and laboratory settings across tumor types, Integrate appropriate strategies for interdisciplinary collaboration and coordination among all members of the healthcare team to optimize the selection and interpretation of PD-L1 biomarker testing to guide clinical decision-making.

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
Suresh S. Ramalingam, MD, FACP, FASCO / Arjun Balar, MD / Yelena Janjigian, MD - Revisiting PD-L1 as an Immunotherapy Biomarker Across the Cancer Spectrum: Current and Emerging Standards of Testing, Scoring, and Assay Interpretation

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast

Play Episode Listen Later Jun 21, 2021 93:59


Go online to PeerView.com/CYY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies have transformed the treatment of many tumors. With the remarkable expansion of checkpoint inhibitors and combinations across the cancer spectrum, reliable predictive biomarkers are essential to guide clinical decisions about treatment selection. PD-L1 expression is the most established immunotherapy biomarker, and several others are in clinical use or showing promise. However, many research questions and practical challenges remain about biomarker testing, scoring, and interpretation in different tumors to identify patients who are most likely to benefit from cancer immunotherapies. This PeerView Clinical and Laboratory Accelerator based on a recent web broadcast provides practical guidance for navigating the complexities of cancer immunotherapy biomarker testing. Oncology and pathology experts focus on the nuances of PD-L1 expression assessment, along with other relevant biomarkers, in different solid tumors and how to use this information to direct clinical decisions regarding treatment selection for appropriate patients. Ongoing research efforts and innovations to refine and expand the role of cancer immunotherapy biomarkers are explored as well. Upon completion of this accredited CE activity, participants should be better able to: Assess the latest evidence on PD-L1 as a pan-tumor biomarker and the rationale for its use to predict benefit from cancer immunotherapies, Analyze practical considerations and complexities of PD-L1 biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, standardization/harmonization options, cut points, digital pathology, artificial intelligence/machine learning, and other nuances, Incorporate the latest evidence and recommendations for PD-L1 biomarker testing in clinical and laboratory settings across tumor types, Integrate appropriate strategies for interdisciplinary collaboration and coordination among all members of the healthcare team to optimize the selection and interpretation of PD-L1 biomarker testing to guide clinical decision-making.

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
Suresh S. Ramalingam, MD, FACP, FASCO / Arjun Balar, MD / Yelena Janjigian, MD - Revisiting PD-L1 as an Immunotherapy Biomarker Across the Cancer Spectrum: Current and Emerging Standards of Testing, Scoring, and Assay Interpretation

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jun 21, 2021 93:30


Go online to PeerView.com/CYY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies have transformed the treatment of many tumors. With the remarkable expansion of checkpoint inhibitors and combinations across the cancer spectrum, reliable predictive biomarkers are essential to guide clinical decisions about treatment selection. PD-L1 expression is the most established immunotherapy biomarker, and several others are in clinical use or showing promise. However, many research questions and practical challenges remain about biomarker testing, scoring, and interpretation in different tumors to identify patients who are most likely to benefit from cancer immunotherapies. This PeerView Clinical and Laboratory Accelerator based on a recent web broadcast provides practical guidance for navigating the complexities of cancer immunotherapy biomarker testing. Oncology and pathology experts focus on the nuances of PD-L1 expression assessment, along with other relevant biomarkers, in different solid tumors and how to use this information to direct clinical decisions regarding treatment selection for appropriate patients. Ongoing research efforts and innovations to refine and expand the role of cancer immunotherapy biomarkers are explored as well. Upon completion of this accredited CE activity, participants should be better able to: Assess the latest evidence on PD-L1 as a pan-tumor biomarker and the rationale for its use to predict benefit from cancer immunotherapies, Analyze practical considerations and complexities of PD-L1 biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, standardization/harmonization options, cut points, digital pathology, artificial intelligence/machine learning, and other nuances, Incorporate the latest evidence and recommendations for PD-L1 biomarker testing in clinical and laboratory settings across tumor types, Integrate appropriate strategies for interdisciplinary collaboration and coordination among all members of the healthcare team to optimize the selection and interpretation of PD-L1 biomarker testing to guide clinical decision-making.

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Suresh S. Ramalingam, MD, FACP, FASCO / Arjun Balar, MD / Yelena Janjigian, MD - Revisiting PD-L1 as an Immunotherapy Biomarker Across the Cancer Spectrum: Current and Emerging Standards of Testing, Scoring, and Assay Interpretation

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Jun 21, 2021 93:59


Go online to PeerView.com/CYY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies have transformed the treatment of many tumors. With the remarkable expansion of checkpoint inhibitors and combinations across the cancer spectrum, reliable predictive biomarkers are essential to guide clinical decisions about treatment selection. PD-L1 expression is the most established immunotherapy biomarker, and several others are in clinical use or showing promise. However, many research questions and practical challenges remain about biomarker testing, scoring, and interpretation in different tumors to identify patients who are most likely to benefit from cancer immunotherapies. This PeerView Clinical and Laboratory Accelerator based on a recent web broadcast provides practical guidance for navigating the complexities of cancer immunotherapy biomarker testing. Oncology and pathology experts focus on the nuances of PD-L1 expression assessment, along with other relevant biomarkers, in different solid tumors and how to use this information to direct clinical decisions regarding treatment selection for appropriate patients. Ongoing research efforts and innovations to refine and expand the role of cancer immunotherapy biomarkers are explored as well. Upon completion of this accredited CE activity, participants should be better able to: Assess the latest evidence on PD-L1 as a pan-tumor biomarker and the rationale for its use to predict benefit from cancer immunotherapies, Analyze practical considerations and complexities of PD-L1 biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, standardization/harmonization options, cut points, digital pathology, artificial intelligence/machine learning, and other nuances, Incorporate the latest evidence and recommendations for PD-L1 biomarker testing in clinical and laboratory settings across tumor types, Integrate appropriate strategies for interdisciplinary collaboration and coordination among all members of the healthcare team to optimize the selection and interpretation of PD-L1 biomarker testing to guide clinical decision-making.

PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast
Suresh S. Ramalingam, MD, FACP, FASCO / Arjun Balar, MD / Yelena Janjigian, MD - Revisiting PD-L1 as an Immunotherapy Biomarker Across the Cancer Spectrum: Current and Emerging Standards of Testing, Scoring, and Assay Interpretation

PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast

Play Episode Listen Later Jun 21, 2021 93:59


Go online to PeerView.com/CYY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies have transformed the treatment of many tumors. With the remarkable expansion of checkpoint inhibitors and combinations across the cancer spectrum, reliable predictive biomarkers are essential to guide clinical decisions about treatment selection. PD-L1 expression is the most established immunotherapy biomarker, and several others are in clinical use or showing promise. However, many research questions and practical challenges remain about biomarker testing, scoring, and interpretation in different tumors to identify patients who are most likely to benefit from cancer immunotherapies. This PeerView Clinical and Laboratory Accelerator based on a recent web broadcast provides practical guidance for navigating the complexities of cancer immunotherapy biomarker testing. Oncology and pathology experts focus on the nuances of PD-L1 expression assessment, along with other relevant biomarkers, in different solid tumors and how to use this information to direct clinical decisions regarding treatment selection for appropriate patients. Ongoing research efforts and innovations to refine and expand the role of cancer immunotherapy biomarkers are explored as well. Upon completion of this accredited CE activity, participants should be better able to: Assess the latest evidence on PD-L1 as a pan-tumor biomarker and the rationale for its use to predict benefit from cancer immunotherapies, Analyze practical considerations and complexities of PD-L1 biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, standardization/harmonization options, cut points, digital pathology, artificial intelligence/machine learning, and other nuances, Incorporate the latest evidence and recommendations for PD-L1 biomarker testing in clinical and laboratory settings across tumor types, Integrate appropriate strategies for interdisciplinary collaboration and coordination among all members of the healthcare team to optimize the selection and interpretation of PD-L1 biomarker testing to guide clinical decision-making.

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Suresh S. Ramalingam, MD, FACP, FASCO / Arjun Balar, MD / Yelena Janjigian, MD - Revisiting PD-L1 as an Immunotherapy Biomarker Across the Cancer Spectrum: Current and Emerging Standards of Testing, Scoring, and Assay Interpretation

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jun 21, 2021 93:30


Go online to PeerView.com/CYY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies have transformed the treatment of many tumors. With the remarkable expansion of checkpoint inhibitors and combinations across the cancer spectrum, reliable predictive biomarkers are essential to guide clinical decisions about treatment selection. PD-L1 expression is the most established immunotherapy biomarker, and several others are in clinical use or showing promise. However, many research questions and practical challenges remain about biomarker testing, scoring, and interpretation in different tumors to identify patients who are most likely to benefit from cancer immunotherapies. This PeerView Clinical and Laboratory Accelerator based on a recent web broadcast provides practical guidance for navigating the complexities of cancer immunotherapy biomarker testing. Oncology and pathology experts focus on the nuances of PD-L1 expression assessment, along with other relevant biomarkers, in different solid tumors and how to use this information to direct clinical decisions regarding treatment selection for appropriate patients. Ongoing research efforts and innovations to refine and expand the role of cancer immunotherapy biomarkers are explored as well. Upon completion of this accredited CE activity, participants should be better able to: Assess the latest evidence on PD-L1 as a pan-tumor biomarker and the rationale for its use to predict benefit from cancer immunotherapies, Analyze practical considerations and complexities of PD-L1 biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, standardization/harmonization options, cut points, digital pathology, artificial intelligence/machine learning, and other nuances, Incorporate the latest evidence and recommendations for PD-L1 biomarker testing in clinical and laboratory settings across tumor types, Integrate appropriate strategies for interdisciplinary collaboration and coordination among all members of the healthcare team to optimize the selection and interpretation of PD-L1 biomarker testing to guide clinical decision-making.

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
Suresh S. Ramalingam, MD, FACP, FASCO / Arjun Balar, MD / Yelena Janjigian, MD - Revisiting PD-L1 as an Immunotherapy Biomarker Across the Cancer Spectrum: Current and Emerging Standards of Testing, Scoring, and Assay Interpretation

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast

Play Episode Listen Later Jun 21, 2021 93:59


Go online to PeerView.com/CYY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies have transformed the treatment of many tumors. With the remarkable expansion of checkpoint inhibitors and combinations across the cancer spectrum, reliable predictive biomarkers are essential to guide clinical decisions about treatment selection. PD-L1 expression is the most established immunotherapy biomarker, and several others are in clinical use or showing promise. However, many research questions and practical challenges remain about biomarker testing, scoring, and interpretation in different tumors to identify patients who are most likely to benefit from cancer immunotherapies. This PeerView Clinical and Laboratory Accelerator based on a recent web broadcast provides practical guidance for navigating the complexities of cancer immunotherapy biomarker testing. Oncology and pathology experts focus on the nuances of PD-L1 expression assessment, along with other relevant biomarkers, in different solid tumors and how to use this information to direct clinical decisions regarding treatment selection for appropriate patients. Ongoing research efforts and innovations to refine and expand the role of cancer immunotherapy biomarkers are explored as well. Upon completion of this accredited CE activity, participants should be better able to: Assess the latest evidence on PD-L1 as a pan-tumor biomarker and the rationale for its use to predict benefit from cancer immunotherapies, Analyze practical considerations and complexities of PD-L1 biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, standardization/harmonization options, cut points, digital pathology, artificial intelligence/machine learning, and other nuances, Incorporate the latest evidence and recommendations for PD-L1 biomarker testing in clinical and laboratory settings across tumor types, Integrate appropriate strategies for interdisciplinary collaboration and coordination among all members of the healthcare team to optimize the selection and interpretation of PD-L1 biomarker testing to guide clinical decision-making.

PeerView Gastroenterology CME/CNE/CPE Video Podcast
Suresh S. Ramalingam, MD, FACP, FASCO / Arjun Balar, MD / Yelena Janjigian, MD - Revisiting PD-L1 as an Immunotherapy Biomarker Across the Cancer Spectrum: Current and Emerging Standards of Testing, Scoring, and Assay Interpretation

PeerView Gastroenterology CME/CNE/CPE Video Podcast

Play Episode Listen Later Jun 21, 2021 93:59


Go online to PeerView.com/CYY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies have transformed the treatment of many tumors. With the remarkable expansion of checkpoint inhibitors and combinations across the cancer spectrum, reliable predictive biomarkers are essential to guide clinical decisions about treatment selection. PD-L1 expression is the most established immunotherapy biomarker, and several others are in clinical use or showing promise. However, many research questions and practical challenges remain about biomarker testing, scoring, and interpretation in different tumors to identify patients who are most likely to benefit from cancer immunotherapies. This PeerView Clinical and Laboratory Accelerator based on a recent web broadcast provides practical guidance for navigating the complexities of cancer immunotherapy biomarker testing. Oncology and pathology experts focus on the nuances of PD-L1 expression assessment, along with other relevant biomarkers, in different solid tumors and how to use this information to direct clinical decisions regarding treatment selection for appropriate patients. Ongoing research efforts and innovations to refine and expand the role of cancer immunotherapy biomarkers are explored as well. Upon completion of this accredited CE activity, participants should be better able to: Assess the latest evidence on PD-L1 as a pan-tumor biomarker and the rationale for its use to predict benefit from cancer immunotherapies, Analyze practical considerations and complexities of PD-L1 biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, standardization/harmonization options, cut points, digital pathology, artificial intelligence/machine learning, and other nuances, Incorporate the latest evidence and recommendations for PD-L1 biomarker testing in clinical and laboratory settings across tumor types, Integrate appropriate strategies for interdisciplinary collaboration and coordination among all members of the healthcare team to optimize the selection and interpretation of PD-L1 biomarker testing to guide clinical decision-making.

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
Suresh S. Ramalingam, MD, FACP, FASCO / Arjun Balar, MD / Yelena Janjigian, MD - Revisiting PD-L1 as an Immunotherapy Biomarker Across the Cancer Spectrum: Current and Emerging Standards of Testing, Scoring, and Assay Interpretation

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jun 21, 2021 93:59


Go online to PeerView.com/CYY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies have transformed the treatment of many tumors. With the remarkable expansion of checkpoint inhibitors and combinations across the cancer spectrum, reliable predictive biomarkers are essential to guide clinical decisions about treatment selection. PD-L1 expression is the most established immunotherapy biomarker, and several others are in clinical use or showing promise. However, many research questions and practical challenges remain about biomarker testing, scoring, and interpretation in different tumors to identify patients who are most likely to benefit from cancer immunotherapies. This PeerView Clinical and Laboratory Accelerator based on a recent web broadcast provides practical guidance for navigating the complexities of cancer immunotherapy biomarker testing. Oncology and pathology experts focus on the nuances of PD-L1 expression assessment, along with other relevant biomarkers, in different solid tumors and how to use this information to direct clinical decisions regarding treatment selection for appropriate patients. Ongoing research efforts and innovations to refine and expand the role of cancer immunotherapy biomarkers are explored as well. Upon completion of this accredited CE activity, participants should be better able to: Assess the latest evidence on PD-L1 as a pan-tumor biomarker and the rationale for its use to predict benefit from cancer immunotherapies, Analyze practical considerations and complexities of PD-L1 biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, standardization/harmonization options, cut points, digital pathology, artificial intelligence/machine learning, and other nuances, Incorporate the latest evidence and recommendations for PD-L1 biomarker testing in clinical and laboratory settings across tumor types, Integrate appropriate strategies for interdisciplinary collaboration and coordination among all members of the healthcare team to optimize the selection and interpretation of PD-L1 biomarker testing to guide clinical decision-making.

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
Suresh S. Ramalingam, MD, FACP, FASCO / Arjun Balar, MD / Yelena Janjigian, MD - Revisiting PD-L1 as an Immunotherapy Biomarker Across the Cancer Spectrum: Current and Emerging Standards of Testing, Scoring, and Assay Interpretation

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jun 21, 2021 93:30


Go online to PeerView.com/CYY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies have transformed the treatment of many tumors. With the remarkable expansion of checkpoint inhibitors and combinations across the cancer spectrum, reliable predictive biomarkers are essential to guide clinical decisions about treatment selection. PD-L1 expression is the most established immunotherapy biomarker, and several others are in clinical use or showing promise. However, many research questions and practical challenges remain about biomarker testing, scoring, and interpretation in different tumors to identify patients who are most likely to benefit from cancer immunotherapies. This PeerView Clinical and Laboratory Accelerator based on a recent web broadcast provides practical guidance for navigating the complexities of cancer immunotherapy biomarker testing. Oncology and pathology experts focus on the nuances of PD-L1 expression assessment, along with other relevant biomarkers, in different solid tumors and how to use this information to direct clinical decisions regarding treatment selection for appropriate patients. Ongoing research efforts and innovations to refine and expand the role of cancer immunotherapy biomarkers are explored as well. Upon completion of this accredited CE activity, participants should be better able to: Assess the latest evidence on PD-L1 as a pan-tumor biomarker and the rationale for its use to predict benefit from cancer immunotherapies, Analyze practical considerations and complexities of PD-L1 biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, standardization/harmonization options, cut points, digital pathology, artificial intelligence/machine learning, and other nuances, Incorporate the latest evidence and recommendations for PD-L1 biomarker testing in clinical and laboratory settings across tumor types, Integrate appropriate strategies for interdisciplinary collaboration and coordination among all members of the healthcare team to optimize the selection and interpretation of PD-L1 biomarker testing to guide clinical decision-making.

PeerView Clinical Pharmacology CME/CNE/CPE Video
Suresh S. Ramalingam, MD, FACP, FASCO / Arjun Balar, MD / Yelena Janjigian, MD - Revisiting PD-L1 as an Immunotherapy Biomarker Across the Cancer Spectrum: Current and Emerging Standards of Testing, Scoring, and Assay Interpretation

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Jun 21, 2021 93:59


Go online to PeerView.com/CYY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies have transformed the treatment of many tumors. With the remarkable expansion of checkpoint inhibitors and combinations across the cancer spectrum, reliable predictive biomarkers are essential to guide clinical decisions about treatment selection. PD-L1 expression is the most established immunotherapy biomarker, and several others are in clinical use or showing promise. However, many research questions and practical challenges remain about biomarker testing, scoring, and interpretation in different tumors to identify patients who are most likely to benefit from cancer immunotherapies. This PeerView Clinical and Laboratory Accelerator based on a recent web broadcast provides practical guidance for navigating the complexities of cancer immunotherapy biomarker testing. Oncology and pathology experts focus on the nuances of PD-L1 expression assessment, along with other relevant biomarkers, in different solid tumors and how to use this information to direct clinical decisions regarding treatment selection for appropriate patients. Ongoing research efforts and innovations to refine and expand the role of cancer immunotherapy biomarkers are explored as well. Upon completion of this accredited CE activity, participants should be better able to: Assess the latest evidence on PD-L1 as a pan-tumor biomarker and the rationale for its use to predict benefit from cancer immunotherapies, Analyze practical considerations and complexities of PD-L1 biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, standardization/harmonization options, cut points, digital pathology, artificial intelligence/machine learning, and other nuances, Incorporate the latest evidence and recommendations for PD-L1 biomarker testing in clinical and laboratory settings across tumor types, Integrate appropriate strategies for interdisciplinary collaboration and coordination among all members of the healthcare team to optimize the selection and interpretation of PD-L1 biomarker testing to guide clinical decision-making.

PeerView Gastroenterology CME/CNE/CPE Audio Podcast
Suresh S. Ramalingam, MD, FACP, FASCO / Arjun Balar, MD / Yelena Janjigian, MD - Revisiting PD-L1 as an Immunotherapy Biomarker Across the Cancer Spectrum: Current and Emerging Standards of Testing, Scoring, and Assay Interpretation

PeerView Gastroenterology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jun 21, 2021 93:30


Go online to PeerView.com/CYY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies have transformed the treatment of many tumors. With the remarkable expansion of checkpoint inhibitors and combinations across the cancer spectrum, reliable predictive biomarkers are essential to guide clinical decisions about treatment selection. PD-L1 expression is the most established immunotherapy biomarker, and several others are in clinical use or showing promise. However, many research questions and practical challenges remain about biomarker testing, scoring, and interpretation in different tumors to identify patients who are most likely to benefit from cancer immunotherapies. This PeerView Clinical and Laboratory Accelerator based on a recent web broadcast provides practical guidance for navigating the complexities of cancer immunotherapy biomarker testing. Oncology and pathology experts focus on the nuances of PD-L1 expression assessment, along with other relevant biomarkers, in different solid tumors and how to use this information to direct clinical decisions regarding treatment selection for appropriate patients. Ongoing research efforts and innovations to refine and expand the role of cancer immunotherapy biomarkers are explored as well. Upon completion of this accredited CE activity, participants should be better able to: Assess the latest evidence on PD-L1 as a pan-tumor biomarker and the rationale for its use to predict benefit from cancer immunotherapies, Analyze practical considerations and complexities of PD-L1 biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, standardization/harmonization options, cut points, digital pathology, artificial intelligence/machine learning, and other nuances, Incorporate the latest evidence and recommendations for PD-L1 biomarker testing in clinical and laboratory settings across tumor types, Integrate appropriate strategies for interdisciplinary collaboration and coordination among all members of the healthcare team to optimize the selection and interpretation of PD-L1 biomarker testing to guide clinical decision-making.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Suresh S. Ramalingam, MD, FACP, FASCO / Arjun Balar, MD / Yelena Janjigian, MD - Revisiting PD-L1 as an Immunotherapy Biomarker Across the Cancer Spectrum: Current and Emerging Standards of Testing, Scoring, and Assay Interpretation

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jun 21, 2021 93:30


Go online to PeerView.com/CYY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies have transformed the treatment of many tumors. With the remarkable expansion of checkpoint inhibitors and combinations across the cancer spectrum, reliable predictive biomarkers are essential to guide clinical decisions about treatment selection. PD-L1 expression is the most established immunotherapy biomarker, and several others are in clinical use or showing promise. However, many research questions and practical challenges remain about biomarker testing, scoring, and interpretation in different tumors to identify patients who are most likely to benefit from cancer immunotherapies. This PeerView Clinical and Laboratory Accelerator based on a recent web broadcast provides practical guidance for navigating the complexities of cancer immunotherapy biomarker testing. Oncology and pathology experts focus on the nuances of PD-L1 expression assessment, along with other relevant biomarkers, in different solid tumors and how to use this information to direct clinical decisions regarding treatment selection for appropriate patients. Ongoing research efforts and innovations to refine and expand the role of cancer immunotherapy biomarkers are explored as well. Upon completion of this accredited CE activity, participants should be better able to: Assess the latest evidence on PD-L1 as a pan-tumor biomarker and the rationale for its use to predict benefit from cancer immunotherapies, Analyze practical considerations and complexities of PD-L1 biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, standardization/harmonization options, cut points, digital pathology, artificial intelligence/machine learning, and other nuances, Incorporate the latest evidence and recommendations for PD-L1 biomarker testing in clinical and laboratory settings across tumor types, Integrate appropriate strategies for interdisciplinary collaboration and coordination among all members of the healthcare team to optimize the selection and interpretation of PD-L1 biomarker testing to guide clinical decision-making.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Suresh S. Ramalingam, MD, FACP, FASCO - Everything You Need to Know About Biomarkers, Immunotherapies, Combinations, and Other Emerging Approaches for Lung Cancer

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Aug 19, 2020 61:42


Go online to PeerView.com/APK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors have firmly established their role as a major component of the lung cancer treatment arsenal. In the first-line setting of advanced NSCLC, there are a number of monotherapy and combinatorial strategies (such as combining immune checkpoint inhibitors with chemotherapy regimens, antiangiogenic therapies, and other immunotherapies with non-redundant mechanisms of action) that have FDA-approved indications and are recommended in various best practice guidelines. In addition, increasing evidence is supporting the use of immunotherapies in locally advanced and earlier disease settings, including as neoadjuvant and adjuvant treatments in patients with resectable NSCLC. More recently, the immunotherapy era arrived in SCLC, with new approvals in different settings. Other novel therapies have also improved patient outcomes in extensive-stage SCLC, such as transcription inhibitors. This educational on-demand activity based on a recent live webcast features a panel of leading experts who engage in candid conversations about the modern management of lung cancer. In addition to reviewing the essential established and new clinical data and approvals/indications of immunotherapies, combinations, and other novel treatment options for NSCLC and SCLC, they discuss insightful registry and survey findings regarding patient perspectives, experiences, and needs, as well as the increasing importance of individualizing treatment selection and patient engagement in care planning. Evidence reviews are framed with case scenarios to illustrate the nuances of clinical decision-making in the context of a complex treatment landscape and a variety of tumor-, patient-, and treatment-related factors that should inform these decisions. Upon completion of this activity, participants should be better able to: Assess the efficacy/safety profiles and clinical roles of approved and investigational immunotherapies, combinations, and other novel therapies in lung cancer, including NSCLC and SCLC, Evaluate the roles of predictive biomarkers (PD-L1, TMB) and other relevant disease-, and treatment-related factors as well as patient needs and preferences that should be taken into consideration as part of individualized treatment planning and selection for patients with lung cancer, Describe key new research directions and clinical trials evaluating cancer immunotherapy biomarkers, rational immunotherapy-based treatment strategies, and other emerging therapies in different subtypes and settings of NSCLC and SCLC to refine, expand, and maximize the use of optimal therapies throughout the disease continuum, Educate patients with lung cancer and their caregivers about cancer immunotherapies and other treatment options to help them become well-informed participants in their care, Implement individualized, evidence-based, patient-centric treatment plans for patients with lung cancer.

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Suresh S. Ramalingam, MD, FACP, FASCO - Everything You Need to Know About Biomarkers, Immunotherapies, Combinations, and Other Emerging Approaches for Lung Cancer

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Aug 19, 2020 61:46


Go online to PeerView.com/APK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors have firmly established their role as a major component of the lung cancer treatment arsenal. In the first-line setting of advanced NSCLC, there are a number of monotherapy and combinatorial strategies (such as combining immune checkpoint inhibitors with chemotherapy regimens, antiangiogenic therapies, and other immunotherapies with non-redundant mechanisms of action) that have FDA-approved indications and are recommended in various best practice guidelines. In addition, increasing evidence is supporting the use of immunotherapies in locally advanced and earlier disease settings, including as neoadjuvant and adjuvant treatments in patients with resectable NSCLC. More recently, the immunotherapy era arrived in SCLC, with new approvals in different settings. Other novel therapies have also improved patient outcomes in extensive-stage SCLC, such as transcription inhibitors. This educational on-demand activity based on a recent live webcast features a panel of leading experts who engage in candid conversations about the modern management of lung cancer. In addition to reviewing the essential established and new clinical data and approvals/indications of immunotherapies, combinations, and other novel treatment options for NSCLC and SCLC, they discuss insightful registry and survey findings regarding patient perspectives, experiences, and needs, as well as the increasing importance of individualizing treatment selection and patient engagement in care planning. Evidence reviews are framed with case scenarios to illustrate the nuances of clinical decision-making in the context of a complex treatment landscape and a variety of tumor-, patient-, and treatment-related factors that should inform these decisions. Upon completion of this activity, participants should be better able to: Assess the efficacy/safety profiles and clinical roles of approved and investigational immunotherapies, combinations, and other novel therapies in lung cancer, including NSCLC and SCLC, Evaluate the roles of predictive biomarkers (PD-L1, TMB) and other relevant disease-, and treatment-related factors as well as patient needs and preferences that should be taken into consideration as part of individualized treatment planning and selection for patients with lung cancer, Describe key new research directions and clinical trials evaluating cancer immunotherapy biomarkers, rational immunotherapy-based treatment strategies, and other emerging therapies in different subtypes and settings of NSCLC and SCLC to refine, expand, and maximize the use of optimal therapies throughout the disease continuum, Educate patients with lung cancer and their caregivers about cancer immunotherapies and other treatment options to help them become well-informed participants in their care, Implement individualized, evidence-based, patient-centric treatment plans for patients with lung cancer.

PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast
Suresh S. Ramalingam, MD, FACP, FASCO - Everything You Need to Know About Biomarkers, Immunotherapies, Combinations, and Other Emerging Approaches for Lung Cancer

PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast

Play Episode Listen Later Aug 19, 2020 61:46


Go online to PeerView.com/APK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors have firmly established their role as a major component of the lung cancer treatment arsenal. In the first-line setting of advanced NSCLC, there are a number of monotherapy and combinatorial strategies (such as combining immune checkpoint inhibitors with chemotherapy regimens, antiangiogenic therapies, and other immunotherapies with non-redundant mechanisms of action) that have FDA-approved indications and are recommended in various best practice guidelines. In addition, increasing evidence is supporting the use of immunotherapies in locally advanced and earlier disease settings, including as neoadjuvant and adjuvant treatments in patients with resectable NSCLC. More recently, the immunotherapy era arrived in SCLC, with new approvals in different settings. Other novel therapies have also improved patient outcomes in extensive-stage SCLC, such as transcription inhibitors. This educational on-demand activity based on a recent live webcast features a panel of leading experts who engage in candid conversations about the modern management of lung cancer. In addition to reviewing the essential established and new clinical data and approvals/indications of immunotherapies, combinations, and other novel treatment options for NSCLC and SCLC, they discuss insightful registry and survey findings regarding patient perspectives, experiences, and needs, as well as the increasing importance of individualizing treatment selection and patient engagement in care planning. Evidence reviews are framed with case scenarios to illustrate the nuances of clinical decision-making in the context of a complex treatment landscape and a variety of tumor-, patient-, and treatment-related factors that should inform these decisions. Upon completion of this activity, participants should be better able to: Assess the efficacy/safety profiles and clinical roles of approved and investigational immunotherapies, combinations, and other novel therapies in lung cancer, including NSCLC and SCLC, Evaluate the roles of predictive biomarkers (PD-L1, TMB) and other relevant disease-, and treatment-related factors as well as patient needs and preferences that should be taken into consideration as part of individualized treatment planning and selection for patients with lung cancer, Describe key new research directions and clinical trials evaluating cancer immunotherapy biomarkers, rational immunotherapy-based treatment strategies, and other emerging therapies in different subtypes and settings of NSCLC and SCLC to refine, expand, and maximize the use of optimal therapies throughout the disease continuum, Educate patients with lung cancer and their caregivers about cancer immunotherapies and other treatment options to help them become well-informed participants in their care, Implement individualized, evidence-based, patient-centric treatment plans for patients with lung cancer.

PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
Suresh S. Ramalingam, MD, FACP, FASCO - Everything You Need to Know About Biomarkers, Immunotherapies, Combinations, and Other Emerging Approaches for Lung Cancer

PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast

Play Episode Listen Later Aug 19, 2020 61:42


Go online to PeerView.com/APK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors have firmly established their role as a major component of the lung cancer treatment arsenal. In the first-line setting of advanced NSCLC, there are a number of monotherapy and combinatorial strategies (such as combining immune checkpoint inhibitors with chemotherapy regimens, antiangiogenic therapies, and other immunotherapies with non-redundant mechanisms of action) that have FDA-approved indications and are recommended in various best practice guidelines. In addition, increasing evidence is supporting the use of immunotherapies in locally advanced and earlier disease settings, including as neoadjuvant and adjuvant treatments in patients with resectable NSCLC. More recently, the immunotherapy era arrived in SCLC, with new approvals in different settings. Other novel therapies have also improved patient outcomes in extensive-stage SCLC, such as transcription inhibitors. This educational on-demand activity based on a recent live webcast features a panel of leading experts who engage in candid conversations about the modern management of lung cancer. In addition to reviewing the essential established and new clinical data and approvals/indications of immunotherapies, combinations, and other novel treatment options for NSCLC and SCLC, they discuss insightful registry and survey findings regarding patient perspectives, experiences, and needs, as well as the increasing importance of individualizing treatment selection and patient engagement in care planning. Evidence reviews are framed with case scenarios to illustrate the nuances of clinical decision-making in the context of a complex treatment landscape and a variety of tumor-, patient-, and treatment-related factors that should inform these decisions. Upon completion of this activity, participants should be better able to: Assess the efficacy/safety profiles and clinical roles of approved and investigational immunotherapies, combinations, and other novel therapies in lung cancer, including NSCLC and SCLC, Evaluate the roles of predictive biomarkers (PD-L1, TMB) and other relevant disease-, and treatment-related factors as well as patient needs and preferences that should be taken into consideration as part of individualized treatment planning and selection for patients with lung cancer, Describe key new research directions and clinical trials evaluating cancer immunotherapy biomarkers, rational immunotherapy-based treatment strategies, and other emerging therapies in different subtypes and settings of NSCLC and SCLC to refine, expand, and maximize the use of optimal therapies throughout the disease continuum, Educate patients with lung cancer and their caregivers about cancer immunotherapies and other treatment options to help them become well-informed participants in their care, Implement individualized, evidence-based, patient-centric treatment plans for patients with lung cancer.

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
Suresh S. Ramalingam, MD, FACP, FASCO - Everything You Need to Know About Biomarkers, Immunotherapies, Combinations, and Other Emerging Approaches for Lung Cancer

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast

Play Episode Listen Later Aug 19, 2020 61:42


Go online to PeerView.com/APK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors have firmly established their role as a major component of the lung cancer treatment arsenal. In the first-line setting of advanced NSCLC, there are a number of monotherapy and combinatorial strategies (such as combining immune checkpoint inhibitors with chemotherapy regimens, antiangiogenic therapies, and other immunotherapies with non-redundant mechanisms of action) that have FDA-approved indications and are recommended in various best practice guidelines. In addition, increasing evidence is supporting the use of immunotherapies in locally advanced and earlier disease settings, including as neoadjuvant and adjuvant treatments in patients with resectable NSCLC. More recently, the immunotherapy era arrived in SCLC, with new approvals in different settings. Other novel therapies have also improved patient outcomes in extensive-stage SCLC, such as transcription inhibitors. This educational on-demand activity based on a recent live webcast features a panel of leading experts who engage in candid conversations about the modern management of lung cancer. In addition to reviewing the essential established and new clinical data and approvals/indications of immunotherapies, combinations, and other novel treatment options for NSCLC and SCLC, they discuss insightful registry and survey findings regarding patient perspectives, experiences, and needs, as well as the increasing importance of individualizing treatment selection and patient engagement in care planning. Evidence reviews are framed with case scenarios to illustrate the nuances of clinical decision-making in the context of a complex treatment landscape and a variety of tumor-, patient-, and treatment-related factors that should inform these decisions. Upon completion of this activity, participants should be better able to: Assess the efficacy/safety profiles and clinical roles of approved and investigational immunotherapies, combinations, and other novel therapies in lung cancer, including NSCLC and SCLC, Evaluate the roles of predictive biomarkers (PD-L1, TMB) and other relevant disease-, and treatment-related factors as well as patient needs and preferences that should be taken into consideration as part of individualized treatment planning and selection for patients with lung cancer, Describe key new research directions and clinical trials evaluating cancer immunotherapy biomarkers, rational immunotherapy-based treatment strategies, and other emerging therapies in different subtypes and settings of NSCLC and SCLC to refine, expand, and maximize the use of optimal therapies throughout the disease continuum, Educate patients with lung cancer and their caregivers about cancer immunotherapies and other treatment options to help them become well-informed participants in their care, Implement individualized, evidence-based, patient-centric treatment plans for patients with lung cancer.

PeerView Clinical Pharmacology CME/CNE/CPE Video
Suresh S. Ramalingam, MD, FACP, FASCO - Everything You Need to Know About Biomarkers, Immunotherapies, Combinations, and Other Emerging Approaches for Lung Cancer

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Aug 19, 2020 61:46


Go online to PeerView.com/APK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors have firmly established their role as a major component of the lung cancer treatment arsenal. In the first-line setting of advanced NSCLC, there are a number of monotherapy and combinatorial strategies (such as combining immune checkpoint inhibitors with chemotherapy regimens, antiangiogenic therapies, and other immunotherapies with non-redundant mechanisms of action) that have FDA-approved indications and are recommended in various best practice guidelines. In addition, increasing evidence is supporting the use of immunotherapies in locally advanced and earlier disease settings, including as neoadjuvant and adjuvant treatments in patients with resectable NSCLC. More recently, the immunotherapy era arrived in SCLC, with new approvals in different settings. Other novel therapies have also improved patient outcomes in extensive-stage SCLC, such as transcription inhibitors. This educational on-demand activity based on a recent live webcast features a panel of leading experts who engage in candid conversations about the modern management of lung cancer. In addition to reviewing the essential established and new clinical data and approvals/indications of immunotherapies, combinations, and other novel treatment options for NSCLC and SCLC, they discuss insightful registry and survey findings regarding patient perspectives, experiences, and needs, as well as the increasing importance of individualizing treatment selection and patient engagement in care planning. Evidence reviews are framed with case scenarios to illustrate the nuances of clinical decision-making in the context of a complex treatment landscape and a variety of tumor-, patient-, and treatment-related factors that should inform these decisions. Upon completion of this activity, participants should be better able to: Assess the efficacy/safety profiles and clinical roles of approved and investigational immunotherapies, combinations, and other novel therapies in lung cancer, including NSCLC and SCLC, Evaluate the roles of predictive biomarkers (PD-L1, TMB) and other relevant disease-, and treatment-related factors as well as patient needs and preferences that should be taken into consideration as part of individualized treatment planning and selection for patients with lung cancer, Describe key new research directions and clinical trials evaluating cancer immunotherapy biomarkers, rational immunotherapy-based treatment strategies, and other emerging therapies in different subtypes and settings of NSCLC and SCLC to refine, expand, and maximize the use of optimal therapies throughout the disease continuum, Educate patients with lung cancer and their caregivers about cancer immunotherapies and other treatment options to help them become well-informed participants in their care, Implement individualized, evidence-based, patient-centric treatment plans for patients with lung cancer.

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Suresh S. Ramalingam, MD, FACP, FASCO - Everything You Need to Know About Biomarkers, Immunotherapies, Combinations, and Other Emerging Approaches for Lung Cancer

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Aug 19, 2020 61:42


Go online to PeerView.com/APK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors have firmly established their role as a major component of the lung cancer treatment arsenal. In the first-line setting of advanced NSCLC, there are a number of monotherapy and combinatorial strategies (such as combining immune checkpoint inhibitors with chemotherapy regimens, antiangiogenic therapies, and other immunotherapies with non-redundant mechanisms of action) that have FDA-approved indications and are recommended in various best practice guidelines. In addition, increasing evidence is supporting the use of immunotherapies in locally advanced and earlier disease settings, including as neoadjuvant and adjuvant treatments in patients with resectable NSCLC. More recently, the immunotherapy era arrived in SCLC, with new approvals in different settings. Other novel therapies have also improved patient outcomes in extensive-stage SCLC, such as transcription inhibitors. This educational on-demand activity based on a recent live webcast features a panel of leading experts who engage in candid conversations about the modern management of lung cancer. In addition to reviewing the essential established and new clinical data and approvals/indications of immunotherapies, combinations, and other novel treatment options for NSCLC and SCLC, they discuss insightful registry and survey findings regarding patient perspectives, experiences, and needs, as well as the increasing importance of individualizing treatment selection and patient engagement in care planning. Evidence reviews are framed with case scenarios to illustrate the nuances of clinical decision-making in the context of a complex treatment landscape and a variety of tumor-, patient-, and treatment-related factors that should inform these decisions. Upon completion of this activity, participants should be better able to: Assess the efficacy/safety profiles and clinical roles of approved and investigational immunotherapies, combinations, and other novel therapies in lung cancer, including NSCLC and SCLC, Evaluate the roles of predictive biomarkers (PD-L1, TMB) and other relevant disease-, and treatment-related factors as well as patient needs and preferences that should be taken into consideration as part of individualized treatment planning and selection for patients with lung cancer, Describe key new research directions and clinical trials evaluating cancer immunotherapy biomarkers, rational immunotherapy-based treatment strategies, and other emerging therapies in different subtypes and settings of NSCLC and SCLC to refine, expand, and maximize the use of optimal therapies throughout the disease continuum, Educate patients with lung cancer and their caregivers about cancer immunotherapies and other treatment options to help them become well-informed participants in their care, Implement individualized, evidence-based, patient-centric treatment plans for patients with lung cancer.

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Suresh S. Ramalingam, MD, FACP, FASCO - Everything You Need to Know About Biomarkers, Immunotherapies, Combinations, and Other Emerging Approaches for Lung Cancer

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Aug 19, 2020 61:42


Go online to PeerView.com/APK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors have firmly established their role as a major component of the lung cancer treatment arsenal. In the first-line setting of advanced NSCLC, there are a number of monotherapy and combinatorial strategies (such as combining immune checkpoint inhibitors with chemotherapy regimens, antiangiogenic therapies, and other immunotherapies with non-redundant mechanisms of action) that have FDA-approved indications and are recommended in various best practice guidelines. In addition, increasing evidence is supporting the use of immunotherapies in locally advanced and earlier disease settings, including as neoadjuvant and adjuvant treatments in patients with resectable NSCLC. More recently, the immunotherapy era arrived in SCLC, with new approvals in different settings. Other novel therapies have also improved patient outcomes in extensive-stage SCLC, such as transcription inhibitors. This educational on-demand activity based on a recent live webcast features a panel of leading experts who engage in candid conversations about the modern management of lung cancer. In addition to reviewing the essential established and new clinical data and approvals/indications of immunotherapies, combinations, and other novel treatment options for NSCLC and SCLC, they discuss insightful registry and survey findings regarding patient perspectives, experiences, and needs, as well as the increasing importance of individualizing treatment selection and patient engagement in care planning. Evidence reviews are framed with case scenarios to illustrate the nuances of clinical decision-making in the context of a complex treatment landscape and a variety of tumor-, patient-, and treatment-related factors that should inform these decisions. Upon completion of this activity, participants should be better able to: Assess the efficacy/safety profiles and clinical roles of approved and investigational immunotherapies, combinations, and other novel therapies in lung cancer, including NSCLC and SCLC, Evaluate the roles of predictive biomarkers (PD-L1, TMB) and other relevant disease-, and treatment-related factors as well as patient needs and preferences that should be taken into consideration as part of individualized treatment planning and selection for patients with lung cancer, Describe key new research directions and clinical trials evaluating cancer immunotherapy biomarkers, rational immunotherapy-based treatment strategies, and other emerging therapies in different subtypes and settings of NSCLC and SCLC to refine, expand, and maximize the use of optimal therapies throughout the disease continuum, Educate patients with lung cancer and their caregivers about cancer immunotherapies and other treatment options to help them become well-informed participants in their care, Implement individualized, evidence-based, patient-centric treatment plans for patients with lung cancer.

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Suresh S. Ramalingam, MD, FACP, FASCO - Everything You Need to Know About Biomarkers, Immunotherapies, Combinations, and Other Emerging Approaches for Lung Cancer

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Aug 19, 2020 61:46


Go online to PeerView.com/APK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors have firmly established their role as a major component of the lung cancer treatment arsenal. In the first-line setting of advanced NSCLC, there are a number of monotherapy and combinatorial strategies (such as combining immune checkpoint inhibitors with chemotherapy regimens, antiangiogenic therapies, and other immunotherapies with non-redundant mechanisms of action) that have FDA-approved indications and are recommended in various best practice guidelines. In addition, increasing evidence is supporting the use of immunotherapies in locally advanced and earlier disease settings, including as neoadjuvant and adjuvant treatments in patients with resectable NSCLC. More recently, the immunotherapy era arrived in SCLC, with new approvals in different settings. Other novel therapies have also improved patient outcomes in extensive-stage SCLC, such as transcription inhibitors. This educational on-demand activity based on a recent live webcast features a panel of leading experts who engage in candid conversations about the modern management of lung cancer. In addition to reviewing the essential established and new clinical data and approvals/indications of immunotherapies, combinations, and other novel treatment options for NSCLC and SCLC, they discuss insightful registry and survey findings regarding patient perspectives, experiences, and needs, as well as the increasing importance of individualizing treatment selection and patient engagement in care planning. Evidence reviews are framed with case scenarios to illustrate the nuances of clinical decision-making in the context of a complex treatment landscape and a variety of tumor-, patient-, and treatment-related factors that should inform these decisions. Upon completion of this activity, participants should be better able to: Assess the efficacy/safety profiles and clinical roles of approved and investigational immunotherapies, combinations, and other novel therapies in lung cancer, including NSCLC and SCLC, Evaluate the roles of predictive biomarkers (PD-L1, TMB) and other relevant disease-, and treatment-related factors as well as patient needs and preferences that should be taken into consideration as part of individualized treatment planning and selection for patients with lung cancer, Describe key new research directions and clinical trials evaluating cancer immunotherapy biomarkers, rational immunotherapy-based treatment strategies, and other emerging therapies in different subtypes and settings of NSCLC and SCLC to refine, expand, and maximize the use of optimal therapies throughout the disease continuum, Educate patients with lung cancer and their caregivers about cancer immunotherapies and other treatment options to help them become well-informed participants in their care, Implement individualized, evidence-based, patient-centric treatment plans for patients with lung cancer.

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
Suresh S. Ramalingam, MD, FACP, FASCO - Everything You Need to Know About Biomarkers, Immunotherapies, Combinations, and Other Emerging Approaches for Lung Cancer

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast

Play Episode Listen Later Aug 19, 2020 61:46


Go online to PeerView.com/APK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors have firmly established their role as a major component of the lung cancer treatment arsenal. In the first-line setting of advanced NSCLC, there are a number of monotherapy and combinatorial strategies (such as combining immune checkpoint inhibitors with chemotherapy regimens, antiangiogenic therapies, and other immunotherapies with non-redundant mechanisms of action) that have FDA-approved indications and are recommended in various best practice guidelines. In addition, increasing evidence is supporting the use of immunotherapies in locally advanced and earlier disease settings, including as neoadjuvant and adjuvant treatments in patients with resectable NSCLC. More recently, the immunotherapy era arrived in SCLC, with new approvals in different settings. Other novel therapies have also improved patient outcomes in extensive-stage SCLC, such as transcription inhibitors. This educational on-demand activity based on a recent live webcast features a panel of leading experts who engage in candid conversations about the modern management of lung cancer. In addition to reviewing the essential established and new clinical data and approvals/indications of immunotherapies, combinations, and other novel treatment options for NSCLC and SCLC, they discuss insightful registry and survey findings regarding patient perspectives, experiences, and needs, as well as the increasing importance of individualizing treatment selection and patient engagement in care planning. Evidence reviews are framed with case scenarios to illustrate the nuances of clinical decision-making in the context of a complex treatment landscape and a variety of tumor-, patient-, and treatment-related factors that should inform these decisions. Upon completion of this activity, participants should be better able to: Assess the efficacy/safety profiles and clinical roles of approved and investigational immunotherapies, combinations, and other novel therapies in lung cancer, including NSCLC and SCLC, Evaluate the roles of predictive biomarkers (PD-L1, TMB) and other relevant disease-, and treatment-related factors as well as patient needs and preferences that should be taken into consideration as part of individualized treatment planning and selection for patients with lung cancer, Describe key new research directions and clinical trials evaluating cancer immunotherapy biomarkers, rational immunotherapy-based treatment strategies, and other emerging therapies in different subtypes and settings of NSCLC and SCLC to refine, expand, and maximize the use of optimal therapies throughout the disease continuum, Educate patients with lung cancer and their caregivers about cancer immunotherapies and other treatment options to help them become well-informed participants in their care, Implement individualized, evidence-based, patient-centric treatment plans for patients with lung cancer.

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Suresh S. Ramalingam, MD, FACP, FASCO - Chair's Take: Everything You Need to Know About Biomarkers, Immunotherapies, Combinations, and Other Emerging Approaches for Lung Cancer

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 3, 2020 28:05


Go online to PeerView.com/WCZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, Suresh S. Ramalingam, MD, FACP, FASCO, provides a brief recap of the latest practice-changing data informing the use of an expanding arsenal of immune checkpoint inhibitors and combinations in NSCLC, as well as the evolving evidence on immunotherapies, transcription inhibitors, and other novel treatment approaches in SCLC. Upon completion of this activity, participants should be better able to: Assess the efficacy/safety profiles and clinical roles of approved and investigational immunotherapies, combinations, and other novel therapies in lung cancer, including NSCLC and SCLC, Evaluate the roles of predictive biomarkers (PD-L1, TMB) and other relevant disease-, and treatment-related factors as well as patient needs and preferences that should be taken into consideration as part of individualized treatment planning and selection for patients with lung cancer, Describe key new research directions and clinical trials evaluating cancer immunotherapy biomarkers, rational immunotherapy-based treatment strategies, and other emerging therapies in different subtypes and settings of NSCLC and SCLC to refine, expand, and maximize the use of optimal therapies throughout the disease continuum, Educate patients with lung cancer and their caregivers about cancer immunotherapies and other treatment options to help them become well-informed participants in their care, Implement individualized, evidence-based, patient-centric treatment plans for patients with lung cancer.

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
Suresh S. Ramalingam, MD, FACP, FASCO - Chair's Take: Everything You Need to Know About Biomarkers, Immunotherapies, Combinations, and Other Emerging Approaches for Lung Cancer

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast

Play Episode Listen Later Jul 3, 2020 28:23


Go online to PeerView.com/WCZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, Suresh S. Ramalingam, MD, FACP, FASCO, provides a brief recap of the latest practice-changing data informing the use of an expanding arsenal of immune checkpoint inhibitors and combinations in NSCLC, as well as the evolving evidence on immunotherapies, transcription inhibitors, and other novel treatment approaches in SCLC. Upon completion of this activity, participants should be better able to: Assess the efficacy/safety profiles and clinical roles of approved and investigational immunotherapies, combinations, and other novel therapies in lung cancer, including NSCLC and SCLC, Evaluate the roles of predictive biomarkers (PD-L1, TMB) and other relevant disease-, and treatment-related factors as well as patient needs and preferences that should be taken into consideration as part of individualized treatment planning and selection for patients with lung cancer, Describe key new research directions and clinical trials evaluating cancer immunotherapy biomarkers, rational immunotherapy-based treatment strategies, and other emerging therapies in different subtypes and settings of NSCLC and SCLC to refine, expand, and maximize the use of optimal therapies throughout the disease continuum, Educate patients with lung cancer and their caregivers about cancer immunotherapies and other treatment options to help them become well-informed participants in their care, Implement individualized, evidence-based, patient-centric treatment plans for patients with lung cancer.

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
Suresh S. Ramalingam, MD, FACP, FASCO - Chair's Take: Everything You Need to Know About Biomarkers, Immunotherapies, Combinations, and Other Emerging Approaches for Lung Cancer

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 3, 2020 28:05


Go online to PeerView.com/WCZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, Suresh S. Ramalingam, MD, FACP, FASCO, provides a brief recap of the latest practice-changing data informing the use of an expanding arsenal of immune checkpoint inhibitors and combinations in NSCLC, as well as the evolving evidence on immunotherapies, transcription inhibitors, and other novel treatment approaches in SCLC. Upon completion of this activity, participants should be better able to: Assess the efficacy/safety profiles and clinical roles of approved and investigational immunotherapies, combinations, and other novel therapies in lung cancer, including NSCLC and SCLC, Evaluate the roles of predictive biomarkers (PD-L1, TMB) and other relevant disease-, and treatment-related factors as well as patient needs and preferences that should be taken into consideration as part of individualized treatment planning and selection for patients with lung cancer, Describe key new research directions and clinical trials evaluating cancer immunotherapy biomarkers, rational immunotherapy-based treatment strategies, and other emerging therapies in different subtypes and settings of NSCLC and SCLC to refine, expand, and maximize the use of optimal therapies throughout the disease continuum, Educate patients with lung cancer and their caregivers about cancer immunotherapies and other treatment options to help them become well-informed participants in their care, Implement individualized, evidence-based, patient-centric treatment plans for patients with lung cancer.

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Suresh S. Ramalingam, MD, FACP, FASCO - Chair's Take: Everything You Need to Know About Biomarkers, Immunotherapies, Combinations, and Other Emerging Approaches for Lung Cancer

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Jul 3, 2020 28:23


Go online to PeerView.com/WCZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, Suresh S. Ramalingam, MD, FACP, FASCO, provides a brief recap of the latest practice-changing data informing the use of an expanding arsenal of immune checkpoint inhibitors and combinations in NSCLC, as well as the evolving evidence on immunotherapies, transcription inhibitors, and other novel treatment approaches in SCLC. Upon completion of this activity, participants should be better able to: Assess the efficacy/safety profiles and clinical roles of approved and investigational immunotherapies, combinations, and other novel therapies in lung cancer, including NSCLC and SCLC, Evaluate the roles of predictive biomarkers (PD-L1, TMB) and other relevant disease-, and treatment-related factors as well as patient needs and preferences that should be taken into consideration as part of individualized treatment planning and selection for patients with lung cancer, Describe key new research directions and clinical trials evaluating cancer immunotherapy biomarkers, rational immunotherapy-based treatment strategies, and other emerging therapies in different subtypes and settings of NSCLC and SCLC to refine, expand, and maximize the use of optimal therapies throughout the disease continuum, Educate patients with lung cancer and their caregivers about cancer immunotherapies and other treatment options to help them become well-informed participants in their care, Implement individualized, evidence-based, patient-centric treatment plans for patients with lung cancer.

PeerView Clinical Pharmacology CME/CNE/CPE Video
Suresh S. Ramalingam, MD, FACP, FASCO - Chair's Take: Everything You Need to Know About Biomarkers, Immunotherapies, Combinations, and Other Emerging Approaches for Lung Cancer

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Jul 3, 2020 28:23


Go online to PeerView.com/WCZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, Suresh S. Ramalingam, MD, FACP, FASCO, provides a brief recap of the latest practice-changing data informing the use of an expanding arsenal of immune checkpoint inhibitors and combinations in NSCLC, as well as the evolving evidence on immunotherapies, transcription inhibitors, and other novel treatment approaches in SCLC. Upon completion of this activity, participants should be better able to: Assess the efficacy/safety profiles and clinical roles of approved and investigational immunotherapies, combinations, and other novel therapies in lung cancer, including NSCLC and SCLC, Evaluate the roles of predictive biomarkers (PD-L1, TMB) and other relevant disease-, and treatment-related factors as well as patient needs and preferences that should be taken into consideration as part of individualized treatment planning and selection for patients with lung cancer, Describe key new research directions and clinical trials evaluating cancer immunotherapy biomarkers, rational immunotherapy-based treatment strategies, and other emerging therapies in different subtypes and settings of NSCLC and SCLC to refine, expand, and maximize the use of optimal therapies throughout the disease continuum, Educate patients with lung cancer and their caregivers about cancer immunotherapies and other treatment options to help them become well-informed participants in their care, Implement individualized, evidence-based, patient-centric treatment plans for patients with lung cancer.

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Suresh S. Ramalingam, MD, FACP, FASCO - Chair's Take: Everything You Need to Know About Biomarkers, Immunotherapies, Combinations, and Other Emerging Approaches for Lung Cancer

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 3, 2020 28:05


Go online to PeerView.com/WCZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, Suresh S. Ramalingam, MD, FACP, FASCO, provides a brief recap of the latest practice-changing data informing the use of an expanding arsenal of immune checkpoint inhibitors and combinations in NSCLC, as well as the evolving evidence on immunotherapies, transcription inhibitors, and other novel treatment approaches in SCLC. Upon completion of this activity, participants should be better able to: Assess the efficacy/safety profiles and clinical roles of approved and investigational immunotherapies, combinations, and other novel therapies in lung cancer, including NSCLC and SCLC, Evaluate the roles of predictive biomarkers (PD-L1, TMB) and other relevant disease-, and treatment-related factors as well as patient needs and preferences that should be taken into consideration as part of individualized treatment planning and selection for patients with lung cancer, Describe key new research directions and clinical trials evaluating cancer immunotherapy biomarkers, rational immunotherapy-based treatment strategies, and other emerging therapies in different subtypes and settings of NSCLC and SCLC to refine, expand, and maximize the use of optimal therapies throughout the disease continuum, Educate patients with lung cancer and their caregivers about cancer immunotherapies and other treatment options to help them become well-informed participants in their care, Implement individualized, evidence-based, patient-centric treatment plans for patients with lung cancer.

PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast
Suresh S. Ramalingam, MD, FACP, FASCO - Chair's Take: Everything You Need to Know About Biomarkers, Immunotherapies, Combinations, and Other Emerging Approaches for Lung Cancer

PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast

Play Episode Listen Later Jul 3, 2020 28:23


Go online to PeerView.com/WCZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, Suresh S. Ramalingam, MD, FACP, FASCO, provides a brief recap of the latest practice-changing data informing the use of an expanding arsenal of immune checkpoint inhibitors and combinations in NSCLC, as well as the evolving evidence on immunotherapies, transcription inhibitors, and other novel treatment approaches in SCLC. Upon completion of this activity, participants should be better able to: Assess the efficacy/safety profiles and clinical roles of approved and investigational immunotherapies, combinations, and other novel therapies in lung cancer, including NSCLC and SCLC, Evaluate the roles of predictive biomarkers (PD-L1, TMB) and other relevant disease-, and treatment-related factors as well as patient needs and preferences that should be taken into consideration as part of individualized treatment planning and selection for patients with lung cancer, Describe key new research directions and clinical trials evaluating cancer immunotherapy biomarkers, rational immunotherapy-based treatment strategies, and other emerging therapies in different subtypes and settings of NSCLC and SCLC to refine, expand, and maximize the use of optimal therapies throughout the disease continuum, Educate patients with lung cancer and their caregivers about cancer immunotherapies and other treatment options to help them become well-informed participants in their care, Implement individualized, evidence-based, patient-centric treatment plans for patients with lung cancer.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Suresh S. Ramalingam, MD, FACP, FASCO - Chair's Take: Everything You Need to Know About Biomarkers, Immunotherapies, Combinations, and Other Emerging Approaches for Lung Cancer

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 3, 2020 28:05


Go online to PeerView.com/WCZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, Suresh S. Ramalingam, MD, FACP, FASCO, provides a brief recap of the latest practice-changing data informing the use of an expanding arsenal of immune checkpoint inhibitors and combinations in NSCLC, as well as the evolving evidence on immunotherapies, transcription inhibitors, and other novel treatment approaches in SCLC. Upon completion of this activity, participants should be better able to: Assess the efficacy/safety profiles and clinical roles of approved and investigational immunotherapies, combinations, and other novel therapies in lung cancer, including NSCLC and SCLC, Evaluate the roles of predictive biomarkers (PD-L1, TMB) and other relevant disease-, and treatment-related factors as well as patient needs and preferences that should be taken into consideration as part of individualized treatment planning and selection for patients with lung cancer, Describe key new research directions and clinical trials evaluating cancer immunotherapy biomarkers, rational immunotherapy-based treatment strategies, and other emerging therapies in different subtypes and settings of NSCLC and SCLC to refine, expand, and maximize the use of optimal therapies throughout the disease continuum, Educate patients with lung cancer and their caregivers about cancer immunotherapies and other treatment options to help them become well-informed participants in their care, Implement individualized, evidence-based, patient-centric treatment plans for patients with lung cancer.

PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
Suresh S. Ramalingam, MD, FACP, FASCO - Chair's Take: Everything You Need to Know About Biomarkers, Immunotherapies, Combinations, and Other Emerging Approaches for Lung Cancer

PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 3, 2020 28:05


Go online to PeerView.com/WCZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, Suresh S. Ramalingam, MD, FACP, FASCO, provides a brief recap of the latest practice-changing data informing the use of an expanding arsenal of immune checkpoint inhibitors and combinations in NSCLC, as well as the evolving evidence on immunotherapies, transcription inhibitors, and other novel treatment approaches in SCLC. Upon completion of this activity, participants should be better able to: Assess the efficacy/safety profiles and clinical roles of approved and investigational immunotherapies, combinations, and other novel therapies in lung cancer, including NSCLC and SCLC, Evaluate the roles of predictive biomarkers (PD-L1, TMB) and other relevant disease-, and treatment-related factors as well as patient needs and preferences that should be taken into consideration as part of individualized treatment planning and selection for patients with lung cancer, Describe key new research directions and clinical trials evaluating cancer immunotherapy biomarkers, rational immunotherapy-based treatment strategies, and other emerging therapies in different subtypes and settings of NSCLC and SCLC to refine, expand, and maximize the use of optimal therapies throughout the disease continuum, Educate patients with lung cancer and their caregivers about cancer immunotherapies and other treatment options to help them become well-informed participants in their care, Implement individualized, evidence-based, patient-centric treatment plans for patients with lung cancer.

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Suresh S. Ramalingam, MD, FACP, FASCO - Chair's Take: Everything You Need to Know About Biomarkers, Immunotherapies, Combinations, and Other Emerging Approaches for Lung Cancer

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Jul 3, 2020 28:23


Go online to PeerView.com/WCZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, Suresh S. Ramalingam, MD, FACP, FASCO, provides a brief recap of the latest practice-changing data informing the use of an expanding arsenal of immune checkpoint inhibitors and combinations in NSCLC, as well as the evolving evidence on immunotherapies, transcription inhibitors, and other novel treatment approaches in SCLC. Upon completion of this activity, participants should be better able to: Assess the efficacy/safety profiles and clinical roles of approved and investigational immunotherapies, combinations, and other novel therapies in lung cancer, including NSCLC and SCLC, Evaluate the roles of predictive biomarkers (PD-L1, TMB) and other relevant disease-, and treatment-related factors as well as patient needs and preferences that should be taken into consideration as part of individualized treatment planning and selection for patients with lung cancer, Describe key new research directions and clinical trials evaluating cancer immunotherapy biomarkers, rational immunotherapy-based treatment strategies, and other emerging therapies in different subtypes and settings of NSCLC and SCLC to refine, expand, and maximize the use of optimal therapies throughout the disease continuum, Educate patients with lung cancer and their caregivers about cancer immunotherapies and other treatment options to help them become well-informed participants in their care, Implement individualized, evidence-based, patient-centric treatment plans for patients with lung cancer.

ESMO Open
ESMO Presidential Symposium: Final overall survival analysis from the FLAURA trial

ESMO Open

Play Episode Listen Later Sep 26, 2019 6:31


Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis. The phase III trial Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA) showed a significant increase in progression free survival. In the now available finale survival analysis also the overall survival showed a statistical significant increase. Expert: Suresh S. Ramalingam, Winship Cancer Institute of Emory University, Atlanta, GA

trial ga survival emory university esmo winship cancer institute ramalingam osimertinib flaura egfr tki suresh s ramalingam presidential symposium
2013 ASCO Annual Meeting
Crizotinib superior to chemo for advanced ALK positive NSCLC: Dr Suresh S. Ramalingam

2013 ASCO Annual Meeting

Play Episode Listen Later Jun 13, 2013


Dr Ramalingam gives a comment at ASCO 2013 on two papers published in the New England Journal of Medicine confirming crizotinib as superior to chemotherapy for the treatment of previously treated, advanced non-small cell lung cancer (NSCLC) with ALK rearrangement.

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Suresh S. Ramalingam, MD, FACP, FASCO - Everything You Need to Know About Molecular Testing and Targeted Therapies in NSCLC: Essential Guidance for Modern Patient-Centered Precision Lung Cancer Care

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Jan 1, 1970 64:49


Go online to PeerView.com/VVS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The targeted therapy landscape for non–small cell lung cancer (NSCLC) has evolved considerably in recent years, with far-reaching implications for oncologists, pathologists, and other members of the broader lung cancer care team, as well as for patients. This educational activity provides a comprehensive overview of the importance of performing genomic profiling to determine the optimal treatment approach for patients with molecularly altered NSCLC. In addition, essential practical guidance is shared to help match targeted therapies to each patient's genomic alteration for improved outcomes. Experts discuss the advances, new evidence, and best practices related to molecular testing and targeted treatment of NSCLC. Guidance for applying the emerging science to patient care decisions in everyday practice are also shared, along with recommendations and resources for patient education and engagement in care decisions. Upon completion of this activity, participants should be better able to: Evaluate the evolving science and recommendations for molecular testing in lung cancer, including the use of tissue- and blood-based biomarker testing for evaluation of various molecular alterations in advanced/metastatic NSCLC in newly diagnosed patients and those with acquired resistance, Characterize the mechanisms of action, safety/efficacy profiles, and indications of the various approved and investigational targeted therapies for NSCLC in different patient populations (eg, those targeting EGFR, ALK, BRAF, NTRK, RET, MET, HER2, ROS1, KRAS, NRG1, and others), Integrate best practices related to molecular testing through the continuum of advanced NSCLC, and interpretation of results to guide treatment selection, Educate patients with NSCLC and their caregivers about molecular testing and targeted therapy options to help them become well-informed participants in their care, Implement evidence-based, individualized, precision treatment plans for management of molecularly altered NSCLC based on results of molecular testing, specific patient needs and preferences, and other key factors.

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
Suresh S. Ramalingam, MD, FACP, FASCO - Everything You Need to Know About Molecular Testing and Targeted Therapies in NSCLC: Essential Guidance for Modern Patient-Centered Precision Lung Cancer Care

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jan 1, 1970 64:29


Go online to PeerView.com/VVS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The targeted therapy landscape for non–small cell lung cancer (NSCLC) has evolved considerably in recent years, with far-reaching implications for oncologists, pathologists, and other members of the broader lung cancer care team, as well as for patients. This educational activity provides a comprehensive overview of the importance of performing genomic profiling to determine the optimal treatment approach for patients with molecularly altered NSCLC. In addition, essential practical guidance is shared to help match targeted therapies to each patient's genomic alteration for improved outcomes. Experts discuss the advances, new evidence, and best practices related to molecular testing and targeted treatment of NSCLC. Guidance for applying the emerging science to patient care decisions in everyday practice are also shared, along with recommendations and resources for patient education and engagement in care decisions. Upon completion of this activity, participants should be better able to: Evaluate the evolving science and recommendations for molecular testing in lung cancer, including the use of tissue- and blood-based biomarker testing for evaluation of various molecular alterations in advanced/metastatic NSCLC in newly diagnosed patients and those with acquired resistance, Characterize the mechanisms of action, safety/efficacy profiles, and indications of the various approved and investigational targeted therapies for NSCLC in different patient populations (eg, those targeting EGFR, ALK, BRAF, NTRK, RET, MET, HER2, ROS1, KRAS, NRG1, and others), Integrate best practices related to molecular testing through the continuum of advanced NSCLC, and interpretation of results to guide treatment selection, Educate patients with NSCLC and their caregivers about molecular testing and targeted therapy options to help them become well-informed participants in their care, Implement evidence-based, individualized, precision treatment plans for management of molecularly altered NSCLC based on results of molecular testing, specific patient needs and preferences, and other key factors.

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
Suresh S. Ramalingam, MD, FACP, FASCO - Everything You Need to Know About Molecular Testing and Targeted Therapies in NSCLC: Essential Guidance for Modern Patient-Centered Precision Lung Cancer Care

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast

Play Episode Listen Later Jan 1, 1970 64:49


Go online to PeerView.com/VVS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The targeted therapy landscape for non–small cell lung cancer (NSCLC) has evolved considerably in recent years, with far-reaching implications for oncologists, pathologists, and other members of the broader lung cancer care team, as well as for patients. This educational activity provides a comprehensive overview of the importance of performing genomic profiling to determine the optimal treatment approach for patients with molecularly altered NSCLC. In addition, essential practical guidance is shared to help match targeted therapies to each patient's genomic alteration for improved outcomes. Experts discuss the advances, new evidence, and best practices related to molecular testing and targeted treatment of NSCLC. Guidance for applying the emerging science to patient care decisions in everyday practice are also shared, along with recommendations and resources for patient education and engagement in care decisions. Upon completion of this activity, participants should be better able to: Evaluate the evolving science and recommendations for molecular testing in lung cancer, including the use of tissue- and blood-based biomarker testing for evaluation of various molecular alterations in advanced/metastatic NSCLC in newly diagnosed patients and those with acquired resistance, Characterize the mechanisms of action, safety/efficacy profiles, and indications of the various approved and investigational targeted therapies for NSCLC in different patient populations (eg, those targeting EGFR, ALK, BRAF, NTRK, RET, MET, HER2, ROS1, KRAS, NRG1, and others), Integrate best practices related to molecular testing through the continuum of advanced NSCLC, and interpretation of results to guide treatment selection, Educate patients with NSCLC and their caregivers about molecular testing and targeted therapy options to help them become well-informed participants in their care, Implement evidence-based, individualized, precision treatment plans for management of molecularly altered NSCLC based on results of molecular testing, specific patient needs and preferences, and other key factors.

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
Suresh S. Ramalingam, MD, FACP, FASCO - Everything You Need to Know About Molecular Testing and Targeted Therapies in NSCLC: Essential Guidance for Modern Patient-Centered Precision Lung Cancer Care

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jan 1, 1970 64:29


Go online to PeerView.com/VVS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The targeted therapy landscape for non–small cell lung cancer (NSCLC) has evolved considerably in recent years, with far-reaching implications for oncologists, pathologists, and other members of the broader lung cancer care team, as well as for patients. This educational activity provides a comprehensive overview of the importance of performing genomic profiling to determine the optimal treatment approach for patients with molecularly altered NSCLC. In addition, essential practical guidance is shared to help match targeted therapies to each patient's genomic alteration for improved outcomes. Experts discuss the advances, new evidence, and best practices related to molecular testing and targeted treatment of NSCLC. Guidance for applying the emerging science to patient care decisions in everyday practice are also shared, along with recommendations and resources for patient education and engagement in care decisions. Upon completion of this activity, participants should be better able to: Evaluate the evolving science and recommendations for molecular testing in lung cancer, including the use of tissue- and blood-based biomarker testing for evaluation of various molecular alterations in advanced/metastatic NSCLC in newly diagnosed patients and those with acquired resistance, Characterize the mechanisms of action, safety/efficacy profiles, and indications of the various approved and investigational targeted therapies for NSCLC in different patient populations (eg, those targeting EGFR, ALK, BRAF, NTRK, RET, MET, HER2, ROS1, KRAS, NRG1, and others), Integrate best practices related to molecular testing through the continuum of advanced NSCLC, and interpretation of results to guide treatment selection, Educate patients with NSCLC and their caregivers about molecular testing and targeted therapy options to help them become well-informed participants in their care, Implement evidence-based, individualized, precision treatment plans for management of molecularly altered NSCLC based on results of molecular testing, specific patient needs and preferences, and other key factors.

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Suresh S. Ramalingam, MD, FACP, FASCO - Everything You Need to Know About Molecular Testing and Targeted Therapies in NSCLC: Essential Guidance for Modern Patient-Centered Precision Lung Cancer Care

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Jan 1, 1970 64:49


Go online to PeerView.com/VVS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The targeted therapy landscape for non–small cell lung cancer (NSCLC) has evolved considerably in recent years, with far-reaching implications for oncologists, pathologists, and other members of the broader lung cancer care team, as well as for patients. This educational activity provides a comprehensive overview of the importance of performing genomic profiling to determine the optimal treatment approach for patients with molecularly altered NSCLC. In addition, essential practical guidance is shared to help match targeted therapies to each patient's genomic alteration for improved outcomes. Experts discuss the advances, new evidence, and best practices related to molecular testing and targeted treatment of NSCLC. Guidance for applying the emerging science to patient care decisions in everyday practice are also shared, along with recommendations and resources for patient education and engagement in care decisions. Upon completion of this activity, participants should be better able to: Evaluate the evolving science and recommendations for molecular testing in lung cancer, including the use of tissue- and blood-based biomarker testing for evaluation of various molecular alterations in advanced/metastatic NSCLC in newly diagnosed patients and those with acquired resistance, Characterize the mechanisms of action, safety/efficacy profiles, and indications of the various approved and investigational targeted therapies for NSCLC in different patient populations (eg, those targeting EGFR, ALK, BRAF, NTRK, RET, MET, HER2, ROS1, KRAS, NRG1, and others), Integrate best practices related to molecular testing through the continuum of advanced NSCLC, and interpretation of results to guide treatment selection, Educate patients with NSCLC and their caregivers about molecular testing and targeted therapy options to help them become well-informed participants in their care, Implement evidence-based, individualized, precision treatment plans for management of molecularly altered NSCLC based on results of molecular testing, specific patient needs and preferences, and other key factors.

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Suresh S. Ramalingam, MD, FACP, FASCO - Everything You Need to Know About Molecular Testing and Targeted Therapies in NSCLC: Essential Guidance for Modern Patient-Centered Precision Lung Cancer Care

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jan 1, 1970 64:29


Go online to PeerView.com/VVS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The targeted therapy landscape for non–small cell lung cancer (NSCLC) has evolved considerably in recent years, with far-reaching implications for oncologists, pathologists, and other members of the broader lung cancer care team, as well as for patients. This educational activity provides a comprehensive overview of the importance of performing genomic profiling to determine the optimal treatment approach for patients with molecularly altered NSCLC. In addition, essential practical guidance is shared to help match targeted therapies to each patient's genomic alteration for improved outcomes. Experts discuss the advances, new evidence, and best practices related to molecular testing and targeted treatment of NSCLC. Guidance for applying the emerging science to patient care decisions in everyday practice are also shared, along with recommendations and resources for patient education and engagement in care decisions. Upon completion of this activity, participants should be better able to: Evaluate the evolving science and recommendations for molecular testing in lung cancer, including the use of tissue- and blood-based biomarker testing for evaluation of various molecular alterations in advanced/metastatic NSCLC in newly diagnosed patients and those with acquired resistance, Characterize the mechanisms of action, safety/efficacy profiles, and indications of the various approved and investigational targeted therapies for NSCLC in different patient populations (eg, those targeting EGFR, ALK, BRAF, NTRK, RET, MET, HER2, ROS1, KRAS, NRG1, and others), Integrate best practices related to molecular testing through the continuum of advanced NSCLC, and interpretation of results to guide treatment selection, Educate patients with NSCLC and their caregivers about molecular testing and targeted therapy options to help them become well-informed participants in their care, Implement evidence-based, individualized, precision treatment plans for management of molecularly altered NSCLC based on results of molecular testing, specific patient needs and preferences, and other key factors.

PeerView Clinical Pharmacology CME/CNE/CPE Video
Suresh S. Ramalingam, MD, FACP, FASCO - Everything You Need to Know About Molecular Testing and Targeted Therapies in NSCLC: Essential Guidance for Modern Patient-Centered Precision Lung Cancer Care

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Jan 1, 1970 64:49


Go online to PeerView.com/VVS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The targeted therapy landscape for non–small cell lung cancer (NSCLC) has evolved considerably in recent years, with far-reaching implications for oncologists, pathologists, and other members of the broader lung cancer care team, as well as for patients. This educational activity provides a comprehensive overview of the importance of performing genomic profiling to determine the optimal treatment approach for patients with molecularly altered NSCLC. In addition, essential practical guidance is shared to help match targeted therapies to each patient's genomic alteration for improved outcomes. Experts discuss the advances, new evidence, and best practices related to molecular testing and targeted treatment of NSCLC. Guidance for applying the emerging science to patient care decisions in everyday practice are also shared, along with recommendations and resources for patient education and engagement in care decisions. Upon completion of this activity, participants should be better able to: Evaluate the evolving science and recommendations for molecular testing in lung cancer, including the use of tissue- and blood-based biomarker testing for evaluation of various molecular alterations in advanced/metastatic NSCLC in newly diagnosed patients and those with acquired resistance, Characterize the mechanisms of action, safety/efficacy profiles, and indications of the various approved and investigational targeted therapies for NSCLC in different patient populations (eg, those targeting EGFR, ALK, BRAF, NTRK, RET, MET, HER2, ROS1, KRAS, NRG1, and others), Integrate best practices related to molecular testing through the continuum of advanced NSCLC, and interpretation of results to guide treatment selection, Educate patients with NSCLC and their caregivers about molecular testing and targeted therapy options to help them become well-informed participants in their care, Implement evidence-based, individualized, precision treatment plans for management of molecularly altered NSCLC based on results of molecular testing, specific patient needs and preferences, and other key factors.

PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast
Suresh S. Ramalingam, MD, FACP, FASCO - Everything You Need to Know About Molecular Testing and Targeted Therapies in NSCLC: Essential Guidance for Modern Patient-Centered Precision Lung Cancer Care

PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast

Play Episode Listen Later Jan 1, 1970 64:49


Go online to PeerView.com/VVS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The targeted therapy landscape for non–small cell lung cancer (NSCLC) has evolved considerably in recent years, with far-reaching implications for oncologists, pathologists, and other members of the broader lung cancer care team, as well as for patients. This educational activity provides a comprehensive overview of the importance of performing genomic profiling to determine the optimal treatment approach for patients with molecularly altered NSCLC. In addition, essential practical guidance is shared to help match targeted therapies to each patient's genomic alteration for improved outcomes. Experts discuss the advances, new evidence, and best practices related to molecular testing and targeted treatment of NSCLC. Guidance for applying the emerging science to patient care decisions in everyday practice are also shared, along with recommendations and resources for patient education and engagement in care decisions. Upon completion of this activity, participants should be better able to: Evaluate the evolving science and recommendations for molecular testing in lung cancer, including the use of tissue- and blood-based biomarker testing for evaluation of various molecular alterations in advanced/metastatic NSCLC in newly diagnosed patients and those with acquired resistance, Characterize the mechanisms of action, safety/efficacy profiles, and indications of the various approved and investigational targeted therapies for NSCLC in different patient populations (eg, those targeting EGFR, ALK, BRAF, NTRK, RET, MET, HER2, ROS1, KRAS, NRG1, and others), Integrate best practices related to molecular testing through the continuum of advanced NSCLC, and interpretation of results to guide treatment selection, Educate patients with NSCLC and their caregivers about molecular testing and targeted therapy options to help them become well-informed participants in their care, Implement evidence-based, individualized, precision treatment plans for management of molecularly altered NSCLC based on results of molecular testing, specific patient needs and preferences, and other key factors.

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
Suresh S. Ramalingam, MD, FACP, FASCO - Everything You Need to Know About Molecular Testing and Targeted Therapies in NSCLC: Essential Guidance for Modern Patient-Centered Precision Lung Cancer Care

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast

Play Episode Listen Later Jan 1, 1970 64:49


Go online to PeerView.com/VVS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The targeted therapy landscape for non–small cell lung cancer (NSCLC) has evolved considerably in recent years, with far-reaching implications for oncologists, pathologists, and other members of the broader lung cancer care team, as well as for patients. This educational activity provides a comprehensive overview of the importance of performing genomic profiling to determine the optimal treatment approach for patients with molecularly altered NSCLC. In addition, essential practical guidance is shared to help match targeted therapies to each patient's genomic alteration for improved outcomes. Experts discuss the advances, new evidence, and best practices related to molecular testing and targeted treatment of NSCLC. Guidance for applying the emerging science to patient care decisions in everyday practice are also shared, along with recommendations and resources for patient education and engagement in care decisions. Upon completion of this activity, participants should be better able to: Evaluate the evolving science and recommendations for molecular testing in lung cancer, including the use of tissue- and blood-based biomarker testing for evaluation of various molecular alterations in advanced/metastatic NSCLC in newly diagnosed patients and those with acquired resistance, Characterize the mechanisms of action, safety/efficacy profiles, and indications of the various approved and investigational targeted therapies for NSCLC in different patient populations (eg, those targeting EGFR, ALK, BRAF, NTRK, RET, MET, HER2, ROS1, KRAS, NRG1, and others), Integrate best practices related to molecular testing through the continuum of advanced NSCLC, and interpretation of results to guide treatment selection, Educate patients with NSCLC and their caregivers about molecular testing and targeted therapy options to help them become well-informed participants in their care, Implement evidence-based, individualized, precision treatment plans for management of molecularly altered NSCLC based on results of molecular testing, specific patient needs and preferences, and other key factors.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Suresh S. Ramalingam, MD, FACP, FASCO - Everything You Need to Know About Molecular Testing and Targeted Therapies in NSCLC: Essential Guidance for Modern Patient-Centered Precision Lung Cancer Care

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jan 1, 1970 64:29


Go online to PeerView.com/VVS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The targeted therapy landscape for non–small cell lung cancer (NSCLC) has evolved considerably in recent years, with far-reaching implications for oncologists, pathologists, and other members of the broader lung cancer care team, as well as for patients. This educational activity provides a comprehensive overview of the importance of performing genomic profiling to determine the optimal treatment approach for patients with molecularly altered NSCLC. In addition, essential practical guidance is shared to help match targeted therapies to each patient's genomic alteration for improved outcomes. Experts discuss the advances, new evidence, and best practices related to molecular testing and targeted treatment of NSCLC. Guidance for applying the emerging science to patient care decisions in everyday practice are also shared, along with recommendations and resources for patient education and engagement in care decisions. Upon completion of this activity, participants should be better able to: Evaluate the evolving science and recommendations for molecular testing in lung cancer, including the use of tissue- and blood-based biomarker testing for evaluation of various molecular alterations in advanced/metastatic NSCLC in newly diagnosed patients and those with acquired resistance, Characterize the mechanisms of action, safety/efficacy profiles, and indications of the various approved and investigational targeted therapies for NSCLC in different patient populations (eg, those targeting EGFR, ALK, BRAF, NTRK, RET, MET, HER2, ROS1, KRAS, NRG1, and others), Integrate best practices related to molecular testing through the continuum of advanced NSCLC, and interpretation of results to guide treatment selection, Educate patients with NSCLC and their caregivers about molecular testing and targeted therapy options to help them become well-informed participants in their care, Implement evidence-based, individualized, precision treatment plans for management of molecularly altered NSCLC based on results of molecular testing, specific patient needs and preferences, and other key factors.

PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
Suresh S. Ramalingam, MD, FACP, FASCO - Everything You Need to Know About Molecular Testing and Targeted Therapies in NSCLC: Essential Guidance for Modern Patient-Centered Precision Lung Cancer Care

PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jan 1, 1970 64:29


Go online to PeerView.com/VVS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The targeted therapy landscape for non–small cell lung cancer (NSCLC) has evolved considerably in recent years, with far-reaching implications for oncologists, pathologists, and other members of the broader lung cancer care team, as well as for patients. This educational activity provides a comprehensive overview of the importance of performing genomic profiling to determine the optimal treatment approach for patients with molecularly altered NSCLC. In addition, essential practical guidance is shared to help match targeted therapies to each patient's genomic alteration for improved outcomes. Experts discuss the advances, new evidence, and best practices related to molecular testing and targeted treatment of NSCLC. Guidance for applying the emerging science to patient care decisions in everyday practice are also shared, along with recommendations and resources for patient education and engagement in care decisions. Upon completion of this activity, participants should be better able to: Evaluate the evolving science and recommendations for molecular testing in lung cancer, including the use of tissue- and blood-based biomarker testing for evaluation of various molecular alterations in advanced/metastatic NSCLC in newly diagnosed patients and those with acquired resistance, Characterize the mechanisms of action, safety/efficacy profiles, and indications of the various approved and investigational targeted therapies for NSCLC in different patient populations (eg, those targeting EGFR, ALK, BRAF, NTRK, RET, MET, HER2, ROS1, KRAS, NRG1, and others), Integrate best practices related to molecular testing through the continuum of advanced NSCLC, and interpretation of results to guide treatment selection, Educate patients with NSCLC and their caregivers about molecular testing and targeted therapy options to help them become well-informed participants in their care, Implement evidence-based, individualized, precision treatment plans for management of molecularly altered NSCLC based on results of molecular testing, specific patient needs and preferences, and other key factors.

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Suresh S. Ramalingam, MD, FACP, FASCO - Everything You Need to Know About Molecular Testing and Targeted Therapies in NSCLC: Essential Guidance for Modern Patient-Centered Precision Lung Cancer Care

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jan 1, 1970 64:29


Go online to PeerView.com/VVS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The targeted therapy landscape for non–small cell lung cancer (NSCLC) has evolved considerably in recent years, with far-reaching implications for oncologists, pathologists, and other members of the broader lung cancer care team, as well as for patients. This educational activity provides a comprehensive overview of the importance of performing genomic profiling to determine the optimal treatment approach for patients with molecularly altered NSCLC. In addition, essential practical guidance is shared to help match targeted therapies to each patient's genomic alteration for improved outcomes. Experts discuss the advances, new evidence, and best practices related to molecular testing and targeted treatment of NSCLC. Guidance for applying the emerging science to patient care decisions in everyday practice are also shared, along with recommendations and resources for patient education and engagement in care decisions. Upon completion of this activity, participants should be better able to: Evaluate the evolving science and recommendations for molecular testing in lung cancer, including the use of tissue- and blood-based biomarker testing for evaluation of various molecular alterations in advanced/metastatic NSCLC in newly diagnosed patients and those with acquired resistance, Characterize the mechanisms of action, safety/efficacy profiles, and indications of the various approved and investigational targeted therapies for NSCLC in different patient populations (eg, those targeting EGFR, ALK, BRAF, NTRK, RET, MET, HER2, ROS1, KRAS, NRG1, and others), Integrate best practices related to molecular testing through the continuum of advanced NSCLC, and interpretation of results to guide treatment selection, Educate patients with NSCLC and their caregivers about molecular testing and targeted therapy options to help them become well-informed participants in their care, Implement evidence-based, individualized, precision treatment plans for management of molecularly altered NSCLC based on results of molecular testing, specific patient needs and preferences, and other key factors.